Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but are associated with immune-mediated diarrhea and colitis (IMDC). Clostridioides difficile infection (CDI) can cause infectious diarrhea with overlapping symptoms. Thus, we sought to elucidate the characteristics of CDI in patients treated with ICI, in the context of IMDC.

Methods

We conducted a retrospective, single-center study of adult cancer patients (N=421) with ICI exposure from 2015-2020 and a positive stool nucleic acid amplification test and/or enzyme immunoassay for CDI. Baseline characteristics, treatments, and outcomes were compared between patients with and without concurrent IMDC.

Results

Forty-one eligible patients were included, 27 with concurrent IMDC and 14

SUBMITTER: Vasavada S 

PROVIDER: S-EPMC9210781 | biostudies-literature | 2022 Jul-Aug

REPOSITORIES: biostudies-literature